Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 671-675

  Lamharzi, N ^a   Halmos, G ^a   Armatis, P ^a   Schally, A V ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

EGR receptor mRNA; Human cancer cell lines; LH RH receptor mRNA; RT PCR; Southern blot analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN RECEPTOR; MESSENGER RNA; RADIOLIGAND;

ADVERSE DRUG REACTION; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR AFFINITY; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0031906485     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.3.671     Document Type: Article

References (33)

1. 6]luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroid in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989.
2. Emons G and Schally AV: The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod 9: 1364-1379, 1994.
3. Qayum A, Gullick W, Clayton RC, Sikora K and Waxman J: The effects of gonadotropin hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer 62: 96-99, 1990.
4. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, Miyazaki M, Comaru-Schally AM, Yano T and Emons G: In treatment with Gn-RH analogs: controversies and perspectives. Filicori M and Flamigni C (eds). Parthenon, Carnforth, pp33-44, 1996.
5. Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K and Nagy A: Effect of cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptors content of tumors. Breast Cancer Res Treat 40: 129-139, 1996.
6. Nagy A, Armatis P and Schally AV: High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 93: 2464-2469, 1993.
7. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A and Horvath J: Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93: 7269-7273, 1996.
8. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan G, Szepeshazi K and Halmos G: Inhibition of the growth of rat Dunning R-3327-H prostate carcinoma by treatment with cytotoxic analog of luteinizing hormone-releasing hormone (LH-RH) containing 2-pyrrolinodoxorubicin. Int J Oncol 10: 887-889, 1997.
9. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M and Schally AV: Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and Bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 7: 1141-1148, 1997.
10. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Groot K and Armatis P: LH-RH antagonist Cetrorelix (SB-75) and BN antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 31: 164-172, 1997.
11. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K and Armatis P: Growth inhibition of ovarian cancers by cytotoxic analogs of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89: 1803-1809, 1997.
12. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M and Groot K: Down-regulation of pituitary receptors for luteinizing hormone releasing hormone (LH-RH) antagonists Cetrorelix. Proc Natl Acad Sci USA 93: 2398-2402, 1996.
13. Halmos G and Schally AV: Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonists RC-3095. Proc Natl Acad Sci USA 94: 956-960, 1997.
14. Munson PJ and Rodbard DA: A versatile computerized approach for characterization of ligand binding system. Anal Biochem 107: 220-239, 1980.
15. Xu Y-H, Richert N, Ito S, Merlino GT and Pastan I: Characterization of epidermal growth factor receptor gene expression in malignant and normal cell lines. Proc Natl Acad Sci USA 81: 7308-7313, 1984.
16. Kakar SS, Musgrove LC, Devor CD, Sellers JC and Neill JD: Cloning, sequencing and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 189: 289-295, 1992.
17. Gordon AW, Pegues JC, Johnson GR, Kannan B, Auesperg N and Stromberg K: mRNA phenotyping of the major ligands and receptors of the EGF superfamily in human ovarian epithelial cells. Cancer Lett 89: 63-71, 1995.
18. Horvath J, Ertl T, Qin Y, Groot K and Schally AV: LH-RH and its antagonist Cetrorelix inhibit growth of JAR human choriocarcinoma cells in vitro. Int J Oncol 6: 969-975, 1995.
19. Limonta P, Dondi D, Moretti RM, Maggi R and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCAP. J Clin Endocrinol Metab 75: 207-212, 1992.
20. Kadar T, Ben-David M, Pontes JE, Fekete M and Schally AV: Prolactin and luteinizing hormone-releasing hormone receptor in human benign prostate hyperplasia and prostate cancer. Prostate 12: 299-307, 1988.
21. 6]-luteinizing hormone releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841-1846, 1990.
22. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz K-D and Schally AV: High affinity binding and direct antiproliferative effects of LH-RH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993.
23. Pahwa GS, Vollmer G, Knuppen R and Emons G: Photoaffinity labeling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Biochem Biophys Res Commun 161: 1086-1092, 1989.
24. Fekete M, Redding TW, Comaru-Schally AM, Pontes JE, Connelly RW, Srkalovic G and Schally AV: Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin and epidermal growth factor in rat and human prostate cancers and in benign prostatic hyperplasia. Prostate 14: 191-208, 1989.
25. Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz K-D and Emons G: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LH-RH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822, 1995.
26. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E and Motta M: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LnCaP. J Clin Endocrinol Metab 76: 797-800, 1993.
27. Rosner MR: Regulation of the epidermal growth factor receptor by growth modulating agents. Biotechnol Appl Biochem 12: 473-477, 1990.
28. Ewing TM, Murphy LJ and Ng M-L: Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 44: 744-752, 1989.
29. Bertics PJ, Weber W, Cochet C, Pang GYN, Lee CSL, Watts KW and Sutherland RL: Regulation of the epidermal growth factor receptor by phosphorylation. J Cell Biochem 29: 195-208, 1985.
30. Gill GN, Bertics PJ and Santon JB: Epidermal growth factor and its receptor. Mol Cell Endocrinol 51: 169-186, 1987.
31. Friedman BA and Rosner MA: Growth factors modify the epidermal growth factor receptor through multiple pathways. J Cell Biochem 34: 1-11, 1987.
32. Waterfield MD: Epidermal growth factor and related molecules. Lancet i: 1243-1246, 1989.
33. Lund KA, Lazar CS, Chen WS, Walsh BJ, Welsh JB, Herbst JJ, Walton GM, Rosenfeld MG, Gill GN and Wiley HS: Phosphorylation of the epidermal growth factor receptor threonine 654 inhibits ligand-induced internalization and down-regulation. J Biol Chem 265: 20517-20523, 1990.